Sionna Therapeutics (NASDAQ:SION) Shares Up 6.5% – Should You Buy?

Sionna Therapeutics, Inc. (NASDAQ:SION)’s stock price shot up 6.5% during mid-day trading on Tuesday . The company traded as high as $40.43 and last traded at $41.3360. Approximately 97,874 shares traded hands during trading, a decline of 72% from the average daily volume of 349,595 shares. The stock had previously closed at $38.83.

Analysts Set New Price Targets

SION has been the subject of several research reports. Freedom Capital lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. BTIG Research reiterated a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Wall Street Zen cut shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Stifel Nicolaus lifted their price target on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, May 18th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $53.22.

Sionna Therapeutics Price Performance

The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -21.29 and a beta of 1.30. The stock’s fifty day moving average price is $39.91 and its 200-day moving average price is $39.43.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). As a group, equities research analysts predict that Sionna Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Orbimed Advisors Llc sold 184,639 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director owned 2,671,822 shares of the company’s stock, valued at $123,491,612.84. This trade represents a 6.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the transaction, the director owned 2,671,822 shares in the company, valued at $123,491,612.84. This represents a 6.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,717,962 shares of company stock valued at $77,571,889 in the last 90 days. Corporate insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. TD Asset Management Inc grew its holdings in shares of Sionna Therapeutics by 74.3% during the 3rd quarter. TD Asset Management Inc now owns 87,082 shares of the company’s stock valued at $2,561,000 after acquiring an additional 37,116 shares in the last quarter. UBS Group AG raised its holdings in shares of Sionna Therapeutics by 91.1% during the fourth quarter. UBS Group AG now owns 89,177 shares of the company’s stock worth $3,669,000 after acquiring an additional 42,511 shares in the last quarter. Vanguard Group Inc. boosted its position in Sionna Therapeutics by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after purchasing an additional 41,797 shares during the last quarter. Jennison Associates LLC boosted its position in Sionna Therapeutics by 11.8% during the fourth quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock valued at $45,883,000 after purchasing an additional 117,903 shares during the last quarter. Finally, Eventide Asset Management LLC purchased a new position in Sionna Therapeutics in the fourth quarter valued at about $26,290,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.